Tests AZD0120 cell therapy in adults with relapsing or progressive multiple sclerosis

Trial details

Who runs it

AstraZeneca

Trial code

NCT07224373

Record updated

25 August 2026

Original description

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.Read full original descriptionShow less

A Phase 1b, Open-label, Multi-center, Randomized Study Evaluating the Safety and Tolerability of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cells, in Adults With Refractory Relapsing or Progressive Multiple Sclerosis

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.

Exclusion: Any prior CAR-T or CAR-NK cell exposure; Underwent splenectomy within 12 months prior to signing the ICF; Received a solid organ transplant at any time or on an active transplant waiting list; Prior treatment with autologous hematopoietic stem cell transplantation or total lymphoid irradiation; Evidence of clinically significant bleeding or active bleeding diathesis within 90 days before screening; Major surgery within 4 weeks prior to apheresis or lymphodepletion or has surgery planned during the study or within 4 weeks after study treatment administration; Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 1 year after receiving study treatment, whichever is longer; Cardiac conditions or any other significant cardiac condition that would present undue risk to the participant in the investigator's opinion:; Any other central nervous system disease including epilepsy, convulsive seizures, organic encephalopathy syndrome, non-MS related paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease or associated movement disorder, psychosis, CNS vasculitis, or any other neurological disease that may impact the ability to evaluate neurotoxicity. History of a seizure disorder even if the seizure disorder is well controlled with anti-epileptics; Participant has significant psychiatric condition (active or history of); History of other immune-mediated disease that required continued systemic immunosuppression/systemic disease-modifying agents; History of malignancy or ongoing treatment for prior malignancy; Seropositive for HIV or HTLV (including any history of HIV or HTLV); Active viral (any etiology, HBV, HCV) hepatitis are excluded; Participants are excluded from the study if any of the following criteria apply:; Inborn error of immunity and/or primary immunodeficiency; Unwilling or unsafe to proceed with CSF exams based on coagulopathy or anatomy or other considerations in the judgment of the study investigator; Any contraindications to LP; Participants not willing, able, or are unsafe to take MRI scans as per protocol.

Participants are eligible to be included in the study only if all of the following criteria apply:; Age; Age ≥ 18-years-old to ≤ 60-years-old at the time of consent; Type of Participant and Disease Characteristics; Written informed consent in accordance with federal, local, and institutional guidelines; Adequate physiological function and reserve at screening; RMS Cohort Specific Inclusion Criteria; Diagnosis of RMS according to the 2024 McDonald Criteria (Montalban et al 2025) or diagnosis of relapsing, active SPMS according to Lublin et al 2014; Participants should have an EDSS of ≤ 6.5 at screening; Evidence of active disease (clinical relapses and MRI activities within 2 years prior to screening), or intolerance, while on a high efficacy disease-modifying therapy for ≥ 6 months; PMS Cohort Specific Inclusion Criteria; Diagnosis of PPMS according to the 2024 McDonald Criteria (Montalban et al 2025) or non-relapsing SPMS according to Lublin et al 2014; Participants must have an EDSS of ≥ 3.0 and ≤ 6.5 at screening; Inadequate response ≥ 1 heDMT with ≥ 6 months treatment or intolerance.

ClinicalTrials.gov NCT07224373